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Cytomegalovirus (CMV) has highly evolved mechanisms for avoiding detection by the host immune system.
Recently, in the genomes of human and primate CMV, a novel gene comprising segments of noncontiguous
open reading frames was identified and found to have limited predicted homology to endogenous cellular
interleukin-10 (IL-10). Here we investigate the biological activities of the CMV IL-10-like gene product and
show it to possess potent immunosuppressive properties. Both purified bacterium-derived recombinant CMV
IL-10 and CMV IL-10 expressed in supernatants of human cells were found to inhibit proliferation of
mitogen-stimulated peripheral blood mononuclear cells (PBMCs), with specific activity comparable to that of
recombinant human IL-10. In addition, CMV IL-10 expressed from human cells inhibited cytokine synthesis,
as treatment of stimulated PBMCs and monocytes with CMV IL-10 led to a marked decrease in production of
proinflammatory cytokines. Finally, CMV IL-10 was observed to decrease cell surface expression of both major
histocompatibility complex (MHC) class I and class II molecules, while conversely increasing expression of the
nonclassical MHC allele HLA-G. These results demonstrate for the first time that CMV has a biologically
active IL-10 homolog that may contribute to immune evasion during virus infection.
Cytomegalovirus (CMV) is a widespread human pathogen
with the ability to persist as a lifelong latent infection. Success-
ful coexistence with its host is facilitated by numerous mech-
anisms that the virus has acquired for modulating the host
immune system (11). The US2, US3, US6, and US11 gene
products interfere with antigen processing and presentation,
resulting in reduced major histocompatibility complex (MHC)
class I presentation (1). In addition, the UL18 gene product is
an MHC class I homolog that may facilitate evasion of natural
killer cells (2). An -chemokine homolog (encoded by UL146)
that is chemotactic for neutrophils (22) and a -chemokine
receptor (US28 gene product) that binds human chemokines
have also been identified (20). Most recently, a homolog of the
potent immune modulator interleukin-10 (IL-10) was discov-
ered in the genomes of human CMV (HCMV) and rhesus
macaque CMV (RhCMV) (13, 15).
The HCMV and RhCMV IL-10 proteins are distinctive in
that they have only 27 and 25% identity with their host cellular
IL-10 proteins, respectively. They are encoded from noncon-
tiguous stretches in the viral genome, including open reading
frame (ORF) UL111A and adjacent intergenic areas. The
CMV gene structures are distinct from those of the host IL-10
genes in that the HCMV IL-10 gene has two introns and the
RhCMV IL-10 gene has three introns (compared to four in
human and rhesus cellular IL-10 genes). Although the HCMV
genome (strain AD169) was sequenced several years ago (3),
the existence of CMV IL-10 has remained cryptic until re-
cently, probably because of the unusual gene structure and low
homology to cellular IL-10. In contrast, viral IL-10 homologs
have been identified in the genomes of Epstein-Barr virus
(EBV) (12), equine herpesvirus 2 (27), and the orf virus of the
Poxviridae family (7), but these are encoded as contiguous
ORFs generating proteins with 67 to 90% identity to human
IL-10. EBV-encoded BCRF1, the first viral IL-10 homolog
described, displays many of the activities of human IL-10, such
as cytokine synthesis inhibition and macrophage deactivation
(5, 12). Despite the extensive sequence homology with human
IL-10, EBV IL-10 does not stimulate proliferation of B cells
(as human IL-10 does), suggesting that viral IL-10 homologs
may retain only a subset of human IL-10 activities that are
advantageous for the virus.
IL-10 is a pleiotropic cytokine that is important in the reg-
ulation of the immune response. IL-10 was initially identified
as a product of murine Th2 cells that inhibited the prolifera-
tion and effector activity of Th1 cells, although stimulatory
effects on the proliferation of B cells and mast cells have been
reported (19). In addition to inhibiting cytokine production,
IL-10 has been shown to inhibit expression of MHC class II
and adhesion molecules on monocytes, contributing to sup-
pression of the Th1 type response (4, 5). The functional do-
mains of human IL-10 have been mapped to defined regions;
amino acids 8 to 16 were found to induce proliferation of mast
cells, while a nine-amino-acid region at the carboxy terminus
has cytokine synthesis inhibitory function (8). EBV IL-10 is
partially conserved at the carboxy terminus (six of nine resi-
dues) and has been shown to inhibit cytokine synthesis (12).
The HCMV IL-10 homolog has only one conserved residue in
this region, and the RhCMV IL-10 sequence has no amino acid
homology with either rhesus cellular IL-10 or human IL-10 in
this domain, suggesting that the human and primate CMV
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IL-10 homologs may have different activities than human IL-
10.
Despite the low homology of the CMV IL-10-like proteins
with their cellular counterparts, recent evidence suggests that
HCMV IL-10 may bind to the cellular human IL-10 receptor
(13). However, no experimental evidence has previously dem-
onstrated the biological activity or potency of this molecule.
Therefore, we examined whether the CMV IL-10 proteins
were biologically active gene products with properties that
might be favorable to CMV immune evasion. To investigate
this, we developed in vitro assays utilizing the IL-10 homologs
from the HCMV Towne strain (ATCC VR977) and RhCMV
strain 68.1 (ATCC VR677). To demonstrate interspecies con-
servation of activities we expressed both CMV IL-10 genes as
recombinant proteins in human cells. In addition purified re-
combinant HCMV IL-10 was produced in bacteria to elucidate
the potency of this molecule with respect to recombinant hu-
man IL-10. Here we describe the activities of these viral pro-
teins. CMV IL-10 expressed in human cells exhibited profound
inhibition of human and rhesus peripheral blood mononuclear
cell (PBMC) proliferation and decreased the production of
proinflammatory cytokines in PBMC and monocyte cultures.
In addition, CMV IL-10 induced down regulation of cell sur-
face MHC class I and class II proteins on monocytes, while the
nonclassical MHC class I protein HLA-G was up regulated on
the same cells. Additionally purified recombinant bacterium-
expressed HCMV IL-10 demonstrated a specific activity com-
parable to that of recombinant human IL-10 in reduction of
mitogen-stimulated proliferation of PBMCs, and this activity
was inhibited by a monoclonal antibody to the human IL-10
receptor. These results demonstrate that CMV IL-10 possesses
many immunosuppressive properties that may interfere with
the host immune response.
MATERIALS AND METHODS
Cells. PBMCs were obtained from the peripheral blood of healthy rhesus
macaques by hypotonic lysis of red blood cells or from the buffy coats of cells
from healthy human donors by Ficoll density gradient centrifugation. PBMCs
were maintained in RPMI (HyClone) plus 10% fetal calf serum (FCS) (Hy-
Clone) and recombinant human IL-2 (10 ng/ml; R&D Systems). Monocytes were
purified from PBMCs with anti-CD14 microbeads (Miltenyi) and cultured in
RPMI plus 10% FCS.
Recombinant CMV IL-10 expression. Human embryonic kidney (HEK) 293
(ATCC CRL1573) cells were grown in DMEM (HyClone) plus 5% FCS and
transiently transfected with a myc/His-tagged expression vector containing either
the cDNA sequence of RhCMV IL-10 (pcDNA3.1 m/H-RhCMV IL-10) de-
scribed previously (15) or the cDNA sequence of HCMV (Towne) IL-10
(pcDNA3.1 m/H-HCMV IL-10). Cells were transfected with Superfect transfec-
tion reagent according to the manufacturer’s instructions (Qiagen). Supernatants
were collected after 48 h and clarified by low-speed centrifugation, and protein
expression was verified by Western blotting with an anti-poly-His monoclonal
antibody (Invitrogen). Detection was via TMB membrane peroxidase substrate
(Kirkegaard & Perry Laboratories). Mock-conditioned medium was obtained
from cells transfected with the empty vector (pcDNA3.1-m/H; Invitrogen).
The concentration of CMV IL-10 present in culture supernatants was deter-
mined by comparison with a protein standard. Purified recombinant histidine-
tagged fractalkine (R&D Systems) of known concentration was serially diluted
and blotted alongside an equal volume of supernatant samples onto a nitrocel-
lulose membrane using a standard dot blot apparatus. Once the samples dried,
the membrane was washed in Tris-buffered saline (TBS) and then blocked with
TBS–0.05% bovine serum albumin. The membrane was then incubated with
INDIA-Hisprobe-HRP detection reagent (Pierce Chemical Company) and
washed three times in TBS–0.5% Tween 20, and then horseradish peroxidase was
detected via West-Pico HRP detection reagent as per manufacturer’s instruc-
tions (Pierce Chemical Company) and exposure to Kodak X-Omat film. As
fractalkine has a molecular mass of around 90 kDa and that of CMV IL-10 is
around 30 kDa, concentrations were adjusted by a factor of 3.0.
Recombinant HCMV IL-10. Purified recombinant HCMV IL-10 (strain
Towne) was obtained from R&D Systems.
Proliferation assays. Human or rhesus macaque PBMCs were plated in 96-
well culture dishes at a density of 105 cells per well and stimulated with phyto-
hemagglutinin (PHA) (5 g/ml) or concanavalin A (Sigma) in the presence of
either 5 to 50% (vol/vol) supernatants from transfectants expressing CMV IL-10,
the control vector (mock), recombinant HCMV IL-10, or recombinant human
IL-10 (R&D Systems). Where indicated, CMV IL-10 was immunoprecipitated
from the transfectant supernatants by incubation with anti-poly-His antibody (10
g/ml) and protein A-Sepharose beads for 14 h at 4°C. In some assays mono-
clonal antibody to the human IL-10 receptor (R&D Systems) was included at 15
g/ml. The plates were incubated at 37°C for 72 h, and DNA synthesis was
determined by [3H]thymidine uptake (0.25 Ci/well; Amersham) during the last
18 h of culture.
Cytokine ELISA. Human PBMCs or positively selected CD14 monocytes
were plated in 96-well culture dishes at a density of 105 cells per well and
stimulated with PHA or lipopolysaccharide (LPS) (Sigma) in the presence of
mock- or CMV IL-10-conditioned medium. After 48 h, supernatants were har-
vested and cytokine production was measured by sandwich enzyme-linked im-
munosorbent assay (ELISA). Briefly, 96-well microtiter plates (Nalge Nunc)
were coated with anticytokine capture antibody (4 g/ml; anti-alpha interferon
[IFN-], -tumor necrosis factor alpha [TNF-], -granulocyte-macrophage colo-
ny-stimulating factor [GM-CSF], -IL-1, or -IL-6 from R&D Systems) for 16 h
at 4°C. After blocking with 1% bovine serum albumin (in phosphate-buffered
saline), 100 l of culture supernatant was added. After washing, biotinylated
anticytokine antibodies (2 g/ml; R&D Systems) were added, followed by
streptavidin-horseradish peroxidase (Gibco BRL). Detection was via Genzyme
color reagents (Genzyme Diagnostics); the reaction was terminated with 50 l of
2 N HCl solution per well, and samples were read at 450 nm in a microplate
reader (Molecular Devices). Cytokine levels were determined by linear regres-
sion analysis using a standard curve.
Flow cytometry. Monocytes were stained with phycoerythrin-conjugated anti-
bodies to CD54 (immunoglobulin G1 [IgG1]); HLA-DR (IgG2a); HLA-A, -B, or
-C (IgG1); or the appropriate isotype control (Pharmingen) and analyzed using
a FACScan device and CellQuest software (Becton Dickinson). Staining with
antibody 87G directed against HLA-G (14) was followed by incubation with goat
anti-mouse immunoglobulin–phycoerythrin secondary antibody.
RESULTS
CMV IL-10 inhibits PBMC proliferation. To elucidate the
scope of biological activities of CMV IL-10 and to examine
interspecies differences in these activities, recombinant CMV
IL-10 was generated in HEK 293 cells transfected with plasmid
DNA encoding a C-terminal myc/His epitope-tagged CMV
IL-10 protein from either RhCMV strain 68.1 or HCMV strain
Towne. Transfectant supernatants were harvested and exam-
ined by Western blotting with an antibody directed to the
C-terminal poly-His tag. Supernatants from RhCMV IL-10-
transfected cells were found to express a protein of 26 kDa, the
predicted size of the epitope-tagged CMV IL-10 (15), for at
least 48 h posttransfection (Fig. 1A). The HCMV IL-10 pro-
tein appeared as a 30- to 35-kDa protein, consistent with the
predicted size of the protein with glycosylation (13). The dif-
fuse protein band seen for HCMV IL-10 probably results from
variability in the number of carbohydrate residues. In contrast,
the RhCMV IL-10 protein, which lacks the corresponding N-
linked glycosylation site, appeared as a distinct band (Fig. 1A),
suggesting that the RhCMV protein is not glycosylated. The
concentration of recombinant CMV IL-10 was determined by
comparison to an identically histidine-tagged protein (fractal-
kine), assessed in a dot blot assay. All preparations of CMV
IL-10 were reproducibly found to contain between 100 and 600
ng of IL-10/ml.
The effects of CMV IL-10 on PBMC proliferation in the
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absence of other virally produced factors was assessed using a
panel of mitogen-stimulated PBMCs from human and rhesus
macaque donors. Every donor, regardless of species, showed
marked inhibition of proliferation in the presence of RhCMV
IL-10. Due to the greater availability of human PBMC, results
for human PBMC are shown as representative throughout.
Mitogen-stimulated PBMC exhibited robust proliferation, but
this proliferation was inhibited in the presence of RhCMV
IL-10 (Fig. 1B). While conditioned media constituted 50% of
the total culture volume in these experiments, inhibition of
proliferation was observed in cultures containing as little as 5%
RhCMV IL-10-conditioned medium. Proliferation of cells cul-
FIG. 1. Supernatant CMV IL-10 inhibits PBMC proliferation. (A) Western blot analysis of supernatants from transfected HEK 293 cells with
an anti-poly-His antibody. Cells were transiently transfected with pcDNA3.1-m/H-RhCMV IL-10, pcDNA3.1-m/H-HCMV IL-10, or an empty
vector control (mock). MW, molecular weight marker (sizes at right, in thousands). (B) PBMCs from healthy human donors were stimulated with
PHA for 72 h in the presence of RhCMV IL-10 or mock supernatants. Proliferation was measured by [3H]thymidine uptake during the final 18 h
of culture. RhCMV IL-10 was immunoprecipitated from conditioned medium with an anti-poly-His antibody (CMV IL-10  Ab). Error bars,
standard deviations. (C) PBMCs from nine human donors were tested for effects on proliferation in the presence of HCMV IL-10-conditioned
medium or recombinant human IL-10 (1 g/ml). Results are expressed as percent increase in proliferation relative to control cultures from the
same donor. The horizontal bar indicates mean change in proliferation for all donors.
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tured in the presence of the mock-conditioned medium was
not found to differ from that of cells cultured in fresh RPMI.
To confirm that the inhibitory activity was solely a province of
CMV IL-10, culture supernatants were depleted of RhCMV
IL-10 by adsorption with an antibody directed to the histidine
tag. This resulted in a near total restoration of PBMC prolif-
eration to levels observed with mock medium (Fig. 1B). In the
representative experiment shown, RhCMV IL-10 inhibited the
proliferation of human PBMC; however, equivalent inhibition
of rhesus PBMC proliferation was also seen. Likewise, super-
natant HCMV IL-10 was found to substantially reduce prolif-
eration of human PBMC (data not shown), suggesting that
both HCMV and RhCMV IL-10 homologs can suppress the
replication of immune cells.
To compare this activity to that of the endogenous IL-10 a
bank of PBMC samples was stimulated in the presence of
HCMV IL-10 or recombinant human IL-10. While HCMV
IL-10 inhibited PBMC proliferation for all donors tested (57 to
91% inhibition), variability was observed with human IL-10
treatment. PBMC proliferation for four donors was inhibited
in the presence of recombinant human IL-10 at a concentra-
tion of 1 g/ml (16 to 81% inhibition), while four other donors
showed enhanced proliferation (increases of 24 to 194%) and
one donor showed modest enhancement. The differing effects
of recombinant human IL-10 on PBMC may reflect not only
variability among human donors but also the mixed population
of cells within the PBMC culture. It has been documented that
human IL-10 can have inhibitory effects on monocytes and
CD4 T cells while having stimulatory effects on B cells and
CD8 T cells (19); thus, increased proliferation of some
PBMC cultures could represent outgrowth of these cell types.
In contrast, HCMV IL-10 suppressed proliferation over a wide
range of concentrations on PBMC cultures from multiple do-
nors. These data may suggest that HCMV IL-10 lacks some of
the stimulatory activities of human IL-10.
CMV IL-10 inhibits cytokine synthesis. The hallmark activ-
ity of human IL-10 is inhibition of cytokine synthesis; there-
fore, we examined whether CMV IL-10 would alter the level of
cytokine production in PBMC cultures. PHA-stimulated hu-
man PBMCs were cultured in the presence of mock-, HCMV
IL-10-, or RhCMV IL-10-conditioned medium. After 48 h, the
supernatants from these cultures were assayed for cytokine
levels by ELISA. While control PBMC cultures produced
IFN- in response to PHA stimulation, cytokine levels were
decreased in cultures containing RhCMV IL-10 or HCMV
IL-10 (Fig. 2). IFN- production was almost completely abol-
ished in the presence of either viral cytokine. As an additional
control, PBMC cultures were treated with recombinant human
IL-10 (1 g/ml), which also dramatically inhibited cytokine
production. The results demonstrate that, like human IL-10,
HCMV and RhCMV IL-10 homologs can exert profound in-
hibition of proinflammatory cytokine production by human
leukocytes.
Because PBMC cultures represent a mixed population of
cells, we next examined the effects of CMV IL-10 on a homog-
enous cell population. Primary human monocytes were puri-
fied from PBMCs by positive selection with CD14 microbeads.
Flow cytometric analysis revealed the resulting cell population
to be 99% CD14 positive (data not shown). Monocytes were
stimulated with LPS in the presence of mock- or CMV IL-10-
conditioned medium or recombinant human IL-10. Superna-
tants from these cultures were harvested after 48 h and assayed
for proinflammatory cytokines by ELISA. In LPS-stimulated
monocyte cultures, a robust dose-dependent production of IL-
1, IL-6, GM-CSF, and TNF- was observed, and this produc-
tion was greatly reduced in the presence of HCMV IL-10 or
recombinant human IL-10. (Fig. 3). Similar results were ob-
served upon treatment of human monocytes with RhCMV
IL-10 (data not shown). Thus, CMV-encoded IL-10 has direct
suppressive effects on monocytes, causing a profound decrease
in the production of immunoregulatory cytokines.
Cell surface MHC expression is altered by CMV IL-10.
IL-10 has been reported to lead to decreased levels of MHC
class II molecules and ICAM-1 on monocytes (5, 31), a puta-
tive mechanism by which immune responses are modulated
and homeostasis is maintained. Decreased cellular surveillance
may also potentiate viral infection. Human LPS-stimulated
monocytes were first treated with RhCMV IL-10. Flow cyto-
metric analysis showed that cell surface expression of ICAM-1
on LPS-stimulated monocytes was not significantly affected by
RhCMV IL-10 treatment (Fig. 4, left panels). In contrast, cell
surface levels of both MHC class I and class II antigens were
reduced on the entire cell population by incubation with
RhCMV IL-10 (Fig. 4, center panels). MHC class II levels
were decreased by RhCMV IL-10 treatment in every donor
tested, with the mean fluorescence intensity of MHC class II
staining for RhCMV IL-10 treated cells being nearly threefold
lower than that for cells treated with the mock-conditioned
medium for all donors. The effect of RhCMV IL-10 on mono-
cyte MHC class I protein expression was more variable; de-
creased cell surface expression was observed in four of six
donors, while two of six donors were unaffected. This may
reflect donor variability or differences in cellular activation
states. Similar results were obtained following treatment with
HCMV IL-10 (data not shown). Overall, CMV IL-10 treat-
FIG. 2. CMV IL-10 inhibits cytokine production by activated hu-
man PBMCs. PHA-stimulated PBMCs were incubated in the presence
of mock-, RhCMV IL-10-, or HCMV IL-10-conditioned medium or
recombinant human IL-10 (1 g/ml). Supernatants were harvested
after 48 h and assayed for IFN- production by sandwich ELISA.
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ment was observed to lead to decreased cell surface expression
of both class I and class II MHC molecules on LPS stimulated
monocytes, a scenario that may contribute to viral escape from
immune surveillance.
Finally, we examined the ability of CMV IL-10 to influence
expression of nonclassical MHC antigens. HLA-G has been
observed to confer protection from natural killer cell-mediated
lysis (28), and human IL-10 has been linked to HLA-G up
regulation on monocytes and trophoblasts (18). Since other
CMV proteins have been implicated in the resistance of in-
fected cells to NK cell lysis (11), we asked whether CMV IL-10
might play a role in evading detection by NK cells. Again cells
were treated with supernatants containing RhCMV IL-10. As
shown in Fig. 4, the intensity of HLA-G cell surface staining
was increased following RhCMV IL-10 treatment (right pan-
els). Similar results were seen with HCMV IL-10-containing
supernatants. Up regulation of cell surface HLA-G expression
was seen in all donors tested. Thus, in contrast to the decreased
cell surface expression of classical MHC class I molecules
observed in the presence of CMV IL-10, levels of HLA-G
expression on monocytes were increased. The results demon-
strate that CMV IL-10 modulates multiple aspects of the cell-
mediated immune response by effecting major changes in class
I and class II MHC expression.
Recombinant HCMV IL-10 functions through the IL-10 re-
ceptor. To more directly compare the activities of CMV IL-10
and human IL-10, purified recombinant HCMV IL-10 was
obtained (R&D Systems). Recombinant human or CMV IL-10
was serially diluted, and their effects on PHA-stimulated pro-
liferation of PBMC were measured by tritium incorporation.
As with the CMV IL-10 supernatants, the recombinant HCMV
IL-10 had inhibitory effects on proliferation. Both molecules
significantly inhibited proliferation down to 10 to 100 pg/ml in
replicate assays (Fig. 5A and B), suggesting that the molecules
have a comparable specific activity in this assay.
To ascertain that the inhibitory activity was modulated spe-
cifically through the IL-10 receptor, the assay was repeated in
the presence of neutralizing antibody to the human IL-10 re-
ceptor. Monoclonal anti-human IL-10 receptor antibody mark-
edly increased proliferation of PBMCs at all assay points (Fig.
5C and D, gray bars) compared to parallel samples with no
antibody (Fig. 5C and D, black bars), probably through neu-
tralizing endogenous IL-10 produced by the cells during the
incubation period. This effect of anti-IL-10 receptor antibodies
FIG. 3. HCMV IL-10 inhibits expression of proinflammatory cytokines by human monocytes. Monocytes were stimulated with LPS and
incubated in the presence of mock- or HCMV IL-10-conditioned medium or recombinant human IL-10 (rhIL-10) (1 g/ml). Supernatants were
harvested after 48 h and assayed for IL-1, IL-6, GM-CSF, and TNF- production by sandwich ELISA. Error bars, standard deviations.
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on PBMC proliferation is a typical observation in assays of this
nature (M. Howard, personal communication). However the
antibody also neutralized the effects of the presumably greater
quantity of exogenously provided recombinant human IL-10
(Fig. 5C) and recombinant HCMV IL-10 (Fig. 5D). Only high
levels of recombinant protein were able to inhibit proliferation
of PBMCs compared to the RPMI control. These results dem-
onstrate that recombinant HCMV IL-10 has strong antiprolif-
erative activity, comparable to that of human IL-10, and me-
diates its activity through the human IL-10 receptor.
DISCUSSION
Immunosuppression is a well-documented feature of acute
CMV infection (16). Although these effects have in part been
attributed to virus-induced dysfunction of the monocyte/mac-
rophage population, it has been difficult to define factors that
contribute to systemic immunosuppression due to the size and
complexity of the CMV genome. In this report, we demon-
strate that the HCMV- and RhCMV-encoded IL-10 homologs
have a broad spectrum of immunosuppressive properties. The
CMV IL-10 proteins, despite their low homology to endoge-
nous cellular IL-10 proteins, can inhibit PBMC proliferation,
suppress cytokine production, and down regulate the antigen-
presenting and accessory cell functions of monocytes. Hence,
CMV IL-10 may contribute to CMV-induced immunosuppres-
sion and be an important factor in viral pathogenesis.
IL-10 is an important regulator of inflammation; the essen-
tial role of this cytokine in limiting the immune response is
evidenced by chronic inflammatory disease in mice lacking the
IL-10 gene (24). Furthermore, the production of IL-10 by
tumor cells for evasion of immune surveillance has been well
documented (9). The observation that CMV IL-10 inhibits
immune proliferation and cytokine production indicates that
this protein likely plays a major role in the interaction of the
virus with the host immune system. Previous work has shown
that the CMV IL-10 gene is expressed in HCMV-infected cells
(13) and in RhCMV-infected cells, where it was shown to be an
early transcript expressed abundantly during infection (15).
Polyclonal antiserum raised against the RhCMV IL-10 protein
recognizes a 26-kDa band in infected cell lysates, demonstrat-
ing that the protein is expressed during infection. Furthermore,
serum from chronically infected rhesus macaques was found to
recognize the same 26-kDa protein from infected cell lysates as
well as the recombinantly expressed epitope-tagged protein
(15), suggesting that CMV IL-10 is a target of the host immune
response. Given the previous findings, the antiproliferative ac-
tivity of CMV IL-10 observed here in vitro could reflect a
relevant in vivo modulation of the host immune system impor-
tant for viral pathogenesis.
Interestingly, results from our studies suggest that CMV
IL-10 has the capacity to impair the proliferation of a wide
range of cell types at concentrations ranging from 25 up to 250
ng/ml. In contrast, human IL-10 was observed to have both
inhibitory and stimulatory effects on proliferation of cells from
various donors. Stimulation of PBMC proliferation was ob-
served over a range of concentrations of recombinant human
IL-10, from 1 ng to 1 g/ml (data not shown). The stimulatory
activities of human IL-10 on some cell types, including CD8
T cells, have been documented (19, 29). It is interesting to
speculate that this may represent a key difference in activities,
as CD8 T-cell-mediated immunity is crucial in control of
CMV infection both in murine models and in humans follow-
ing bone marrow transplantation (25, 26). Although the levels
of CMV IL-10 produced in vivo during infection have yet to be
determined, the extensive inhibitory effects of CMV IL-10 on
PBMC suggest that the viral homolog may have evolved func-
tions distinct from its cellular counterpart that are beneficial to
virus replication, perhaps underscored by the sequence diver-
gence within functionally important domains.
Despite differences in antiproliferative activity, levels of in-
hibition of cytokine production were comparable and profound
for both CMV IL-10 and human IL-10. Treatment with CMV
FIG. 4. MHC expression is altered by RhCMV IL-10. Flow cytometric analysis of LPS-stimulated monocytes cultured in the presence of mock-
or RhCMV IL-10-conditioned medium. After 48 h the cells were stained for cell surface expression of CD54 (ICAM), MHC class I (HLA-A, -B,
and -C), MHC class II (HLA-DR), and the nonclassical class I MHC molecule HLA-G. Filled histograms represent staining with the indicated
antibody; open histograms indicate isotype controls. The mean fluorescence intensity is indicated in the upper right corner of each plot.
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IL-10 virtually abolished production of cytokines by activated
PBMCs and monocytes, as did treatment with recombinant
human IL-10. In vivo studies with murine CMV have shown
IFN- to be crucial for the antiviral response (10); thus, the
reduction in cytokine production effected by CMV IL-10 may
result in delayed activation and/or recruitment of immune cells
to the sites of virus infection, favoring virus replication and
dissemination. Also striking was the effect of CMV IL-10 on
cell surface levels of MHC class II antigen in our system. MHC
class II expression is induced by IFN-; therefore, down mod-
ulation of class II by CMV IL-10 could be via direct action of
the viral cytokine or through indirect effects resulting from
IFN- suppression. Interestingly, HCMV has been reported to
interfere with transcription of class II genes through disruption
of the Jak/Stat signaling pathway, although the factors medi-
ating this event have not been defined (17). Our observations
demonstrate that CMV IL-10 induces reduction in class II
MHC expression on monocytes, and this correlates with the
finding that CMV IL-10 binds to the cellular IL-10 receptor
and induces signal transduction that leads to Jak/Stat signaling
(13). Human IL-10 is known to activate Stat 1 and Stat 3,
suppressing a number of IFN- inducible genes, including class
II MHC genes (6). Murine CMV has been reported to cause
down regulation of class II MHC antigen expression through
induction of endogenous IL-10 at early times following infec-
tion (23); these same activities are likely carried out directly by
the HCMV and RhCMV IL-10 homologs during infection. In
addition, elevated levels of human IL-10 in plasma have been
reported during CMV infection in some renal transplant re-
cipients (21), suggesting further redundancy in efforts of the
virus to attain replicative advantage by modulation of the host
immune response.
While interference with class II MHC is an effective mech-
anism for suppression of cell-mediated immunity, we have also
observed a role for CMV IL-10 in down modulation of MHC
class I on monocytes. CMV encodes several proteins (US2,
US3, US6, and US11) that interfere with the class I antigen
processing and presentation pathway (11). We have shown that
CMV IL-10 causes decreased surface expression of class I
MHC, a function that has also been demonstrated for cellular
and EBV IL-10 (31, 32). While the mechanism for class I down
modulation has yet to be explored, it is possible that CMV
IL-10 is acting through the regulation of transcription, a check-
point upstream of the actions of other CMV encoded class I
interference proteins.
The down regulation of classical MHC class I molecules
observed in the presence of CMV IL-10 is in direct contrast to
the effects on the nonclassical MHC protein HLA-G. HLA-G
FIG. 5. Recombinant HCMV IL-10 inhibits PBMC proliferation. PBMCs from healthy human donors were stimulated with PHA for 72 h in
the presence of serial dilutions of recombinant HCMV IL-10 (B and D [black bars]) or recombinant human IL-10 (A and C [black bars]).
Proliferation was measured by [3H]thymidine uptake during the final 18 h of culture. Activity of recombinant proteins was abolished by the
presence of monoclonal anti-human IL-10 receptor antibody at 15 g/ml (C and D [gray bars]). Error bars, standard deviations.
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is important in feto-maternal tolerance by inhibiting lysis of
fetal cells by maternal NK cells (28). Expression of HLA-G on
trophoblasts and monocytes has been linked to IL-10 (18). Our
results demonstrate that CMV IL-10 can increase expression
of HLA-G, suggesting that CMV has evolved a novel mecha-
nism for subversion of NK cell reactivity. Another CMV ORF,
UL18, encodes a class I homolog that may confer protection
from NK cell lysis (2) and recently gpUL40 has been impli-
cated in the up regulation of HLA-E, another nonclassical
MHC protein (30). Given the multiple strategies for subver-
sion of the class I antigen presentation system, it would not be
surprising if CMV had acquired several different mechanisms
for avoiding NK cell lysis. Additional investigations are under
way to examine in detail the regulation of HLA-G by CMV
IL-10.
Evasion of immune detection is a central feature of a suc-
cessful latent virus infection. We demonstrate that the HCMV-
and RhCMV-encoded IL-10 homologs have a broad spectrum
of immunosuppressive properties that may be utilized to es-
cape immune detection. Characterization of biological func-
tions conserved by CMV IL-10 contributes to our knowledge
of virus-host interactions and also provides greater under-
standing of the regulation of the host immune system.
ACKNOWLEDGMENTS
We thank D. E. Geraghty (Fred Hutchinson Cancer Research Cen-
ter, Seattle, Wash.) for kindly providing antibody 87G and Jennifer
Burns and Jennifa Gosling for helpful discussions and for critical
reading of the manuscript.
This work was supported in part by NIH grant 1-R01-HL57883 (to
P.A.B.).
REFERENCES
1. Ahn, K., A. Angula, P. Chazal, Y. Yang, and K. Fruh. 1996. Human cyto-
megalovirus inhibits antigen presentation by a sequential multistep process.
Proc. Natl. Acad. Sci. USA 93:10990–10995.
2. Beck, S., and B. G. Barrel. 1988. Human cytomegalovirus encodes a glyco-
protein homologous to MHC class-I antigens. Nature 331:269–272.
3. Chee, M. S., A. T. Bankier, S. Beck, R. Bohni, C. M. Brown, R. Cerny, T.
Horsnell, C. A. Hutchison, T. Kouzarides, J. A. Martignetti, et al. 1990.
Analysis of the protein-coding content of the sequence of human cytomeg-
alovirus strain AD169. Curr. Top. Microbiol. Immunol. 154:125–169.
4. de Waal Malefyt, R., J. Abrams, B. Bennett, C. G. Figdor, and J. E. de Vries.
1991. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes:
an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:
1209–1220.
5. de Waal Malefyt, R., J. Haanen, H. Spits, M. G. Roncarolo, A. te Velde, C.
Figdor, K. Johnson, R. Kastelein, H. Yssel, and J. E. de Vries. 1991. Inter-
leukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T
cell proliferation by diminishing the antigen-presenting capacity of mono-
cytes via downregulation of class II major histocompatibility complex expres-
sion. J. Exp. Med. 174:915–924.
6. Donnelly, R. P., H. Dickensheets, and D. S. Finbloom. 1999. The interleu-
kin-10 signal transduction pathway and regulation of gene expression in
mononuclear phagocytes. J. Interferon Cytokine Res. 19:563–573.
7. Fleming, S. B., C. A. McCaughan, A. E. Andrews, A. D. Nash, and A. A.
Mercer. 1997. A homolog of interleukin-10 is encoded by the poxvirus orf
virus. J. Virol. 71:4857–4861.
8. Gesser, B., H. Leffers, T. Jinquan, C. Vestergaard, N. Kirstein, S. Sindet-
Pedersen, S. L. Jensen, K. Thestrup-Pedersen, and C. G. Larsen. 1997.
Identification of functional domains on human interleukin 10. Proc. Natl.
Acad. Sci. USA 94:14620–14625.
9. Gotlieb, W. H., J. S. Abrams, J. M. Watson, T. J. Velu, J. S. Berek, and O.
Martinez-Maza. 1992. Presence of interleukin 10 (IL-10) in the ascites of
patients with ovarian and other intra-abdominal cancers. Cytokine 4:385–
390.
10. Heise, M. T., and H. W. Virgin. 1995. The T-cell-independent role of gamma
interferon and tumor necrosis factor alpha in macrophage activation during
murine cytomegalovirus and herpes simplex virus infections. J. Virol. 69:
904–909.
11. Hengel, H., W. Brune, and U. H. Koszinowski. 1998. Immune evasion by
cytomegalovirus—survival strategies of a highly adapted opportunist. Trends
Microbiol. 6:190–197.
12. Hsu, D. H., R. de Waal Malefyt, D. F. Fiorentino, M. N. Dang, P. Vieira, J.
de Vries, H. Spits, T. R. Mosmann, and K. W. Moore. 1990. Expression of
interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 250:
830–832.
13. Kotenko, S. V., S. Saccani, L. S. Izotova, O. V. Mirochnitchenko, and S.
Pestka. 2000. Human cytomegalovirus harbors its own unique IL-10 ho-
molog (cmvIL-10). Proc. Natl. Acad. Sci. USA 97:1695–1700.
14. Lee, N., A. R. Malacko, A. Ishitani, M. C. Chen, J. Bajorath, H. Marquardt,
and D. E. Geraghty. 1995. The membrane-bound and soluble forms of
HLA-G bind identical sets of endogenous peptides but differ with respect to
TAP association. Immunity 3:591–600.
15. Lockridge, K. M., S.-S. Zhou, R. H. Kravitz, J. L. Johnson, E. T. Sawal, E. L.
Blewett, and P. A. Barry. 2000. Primate cytomegaloviruses encode and ex-
press an IL-10-like protein. Virology 268:272–280.
16. McChesney, M. B., and M. B. Oldstone. 1987. Viruses perturb lymphocyte
functions: selected principles characterizing virus-induced immunosuppres-
sion. Annu. Rev. Immunol. 5:279–304.
17. Miller, D. M., B. M. Rahill, J. M. Boss, M. D. Lairmore, J. E. Durbin, W. J.
Waldman, and D. D. Sedmak. 1998. Human cytomegalovirus inhibits major
histocompatibility complex class II expression by disruption of the Jak/Stat
pathway. J. Exp. Med. 187:675–683.
18. Moreau, P., F. Adrian-Cabestro, C. Menier, V. Guiard, L. Gourand, J.
Dausset, E. D. Carosella, and P. Paul. 1999. IL-10 selectively induces
HLA-G expression in human trophoblasts and monocytes. Int. Immunol.
11:803–811.
19. Mosmann, T. R. 1994. Properties and functions of interleukin-10. Adv.
Immunol. 56:1–26.
20. Neote, K., D. DiGregorio, J. Y. Mak, R. Horuk, and T. J. Schall. 1993.
Molecular cloning, functional expression, and signaling characteristics of a
C-C chemokine receptor. Cell 72:415–425.
21. Nordoy, I., F. Muller, K. P. Nordal, H. Rollag, E. Lien, P. Aukrust, and S. S.
Froland. 2000. The role of the tumor necrosis factor system and interleu-
kin-10 during cytomegalovirus infection in renal transplant recipients. J. In-
fect. Dis. 181:51–57.
22. Penfold, M. E., D. J. Dairaghi, G. M. Duke, N. Saederup, E. S. Mocarski,
G. W. Kemble, and T. J. Schall. 1999. Cytomegalovirus encodes a potent
alpha chemokine. Proc. Natl. Acad. Sci. USA 96:9839–9844.
23. Redpath, S., A. Angulo, N. R. J. Gascione, and P. Ghazal. 1999. Murine
cytomegalovirus infection down-regulates MHC class II expression on mac-
rophages by induction of IL-10. J. Immunol. 162:6701–6707.
24. Rennick, D., N. Davidson, and D. Berg. 1995. Interleukin-10 gene knock-out
mice: a model of chronic inflammation. Clin. Immunol. Immunopathol.
76:S174–S178.
25. Reusser, P., S. R. Riddell, J. D. Meyers, and P. D. Greenberg. 1991. Cyto-
toxic T-lymphocyte response to cytomegalovirus after human allogeneic
bone marrow transplantation: pattern of recovery and correlation with cy-
tomegalovirus infection and disease. Blood 78:1373–1380.
26. Riddell, S. R., and P. D. Greenberg. 1997. T cell therapy of human CMV and
EBV infection in immunocompromised hosts. Rev. Med. Virol. 7:181–192.
27. Rode, H. J., W. Janssen, A. Rosen-Wolff, J. J. Bugert, P. Thein, Y. Becker,
and G. Darai. 1993. The genome of equine herpesvirus type 2 harbors an
interleukin 10 (IL10)-like gene. Virus Genes 7:111–116.
28. Rouas-Freiss, N., R. M. Goncalves, C. Menier, J. Dausset, and E. D.
Carosella. 1997. Direct evidence to support the role of HLA-G in protecting
the fetus from maternal uterine natural killer cytolysis. Proc. Natl. Acad. Sci.
USA 94:11520–11525.
29. Rowbottom, A. W., M. A. Lepper, R. J. Garland, C. V. Cox, and E. G. Corley.
1999. Interleukin-10-induced CD8 cell proliferation. Immunology 98:80–89.
30. Tomasec, P., V. M. Braud, C. Rickards, M. B. Powell, B. P. McSharry, S.
Gadola, V. Cerundolo, L. K. Borysiewicz, A. J. McMichael, and G. W. G.
Wilkinson. 2000. Surface expression of HLA-E, and inhibitor of natural
killer cells, enhanced by human cytomegalovirus gpUL40. Science 287:1031–
1033.
31. Yue, F. Y., R. Dummer, R. Geertsen, G. Hofbauer, E. Laine, S. Manolio, and
G. Burg. 1997. Interleukin-10 is a growth factor for human melanoma cells
and down-regulates HLA class-I, HLA class-II, and ICAM-1 molecules. Int.
J. Cancer 71:630–637.
32. Zeidler, R., G. Elssner, P. Meissner, S. Uebel, R. Tampo, S. Lazis, and W.
Hammerschmidt. 1997. Downregulation of TAP1 in B lymphocytes by cel-
lular and Epstein-Barr virus encoded interleukin-10. Blood 90:2390–2397.
1292 SPENCER ET AL. J. VIROL.
